A Prospective, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety & Efficacy of Supplementation of Lutein Formulations on Improving Macular Pigment Optical Density in Healthy Adults - Nil

开始日期2023-12-11

申办/合作机构

India Glycols Ltd.

ISRCTN45322893 / CompletedN/AIIT

Fortification with Xanthophylls trial

开始日期2022-02-14

申办/合作机构-

JPRN-UMIN000045933 / CompletedIIT

The effect of the supplementary capsule containing lutein on visual function in college student athletes - The effect of lutein on visual function

开始日期2021-11-01

申办/合作机构-

100 项与叶黄素相关的临床结果

登录后查看更多信息

100 项与叶黄素相关的转化医学

登录后查看更多信息

100 项与叶黄素相关的专利（医药）

登录后查看更多信息

4,683

项与叶黄素相关的文献（医药）

2024-12-01·Computational and structural biotechnology journal

GhLCYε-3 characterized as a lycopene cyclase gene responding to drought stress in cotton

Article

作者: Ni, Kesong ; Lu, Xuke ; Li, Shuyan ; Li, Fei ; Zhang, Yuexin ; Cui, Ruifeng ; Fan, Yapeng ; Huang, Hui ; Chen, Xiugui ; Wang, Junjuan ; Wang, Shuai ; Guo, Lixue ; Zhao, Lanjie ; He, Yunxin ; Ye, Wuwei

Drought stress significantly affects crop productivity. Carotenoids are essential photosynthetic pigment for plants, bacteria, and algae, with signaling and antioxidant functions. Lutein is a crucial branch product in the carotenoid synthesis pathway, which effectively improves the stress tolerance of higher plants. lycopene cyclase, a central enzyme for lutein synthesis, holds great significance in regulating lutein production. This research establishes a correlation between lutein content and stress resistance by measuring the drought resistance and lutein content of various cotton materials. To identify which crucial genes are associated with lutein, the lycopene cyclase family (LCYs) was analyzed. The research found that LCYs form a highly conserved family divided into two subfamilies, LCY-ε (lycopene ε-cyclase) and LCY-β (lycopene β-cyclase). Most members of the LCY family contain photoresponsive elements and abscisic acid elements. qRT-PCR demonstrates showed that most genes responded positively to drought stress, and GhLCYε-3 was expressed significantly differently under drought stress. Virus-induced gene silencing (VIGS) assay showed that the content of GhLCYε-3 was significantly increased with MDA and PRO, and the contents of chlorophyll and lutein were significantly decreased in pYL156 plants. The decrease in GhLCYε-3 expression is speculated to lead to reduced lutein content in vivo, resulting in the accumulation of reactive oxygen species (ROS) and decreased drought tolerance. This research enriched the understanding of LCY gene family and lutein function, and provided a new reference for cotton planting in arid areas.

Synopsis:

Lycopene cyclase plays an important role in enhancing the ability of scavenging ROS and drought resistance of plants.

2024-02-23·Journal of the American Nutrition Association

Current Insights on the Photoprotective Mechanism of the Macular Carotenoids, Lutein and Zeaxanthin: Safety, Efficacy and Bio-Delivery.

Review

作者: Pawan Kumar ; Samudra P Banik ; Sunny E Ohia ; Hiroyoshi Moriyama ; Sanjoy Chakraborty ; Chin-Kun Wang ; Yong Sang Song ; Apurva Goel ; Manashi Bagchi ; Debasis Bagchi

Ocular health has emerged as one of the major issues of global health concern with a decline in quality of life in an aging population, in particular and rise in the number of associated morbidities and mortalities. One of the chief reasons for vision impairment is oxidative damage inflicted to photoreceptors in rods and cone cells by blue light as well as UV radiation. The scenario has been aggravated by unprecedented rise in screen-time during the COVID and post-COVID era. Lutein and Zeaxanthin are oxygenated carotenoids with proven roles in augmentation of ocular health largely by virtue of their antioxidant properties and protective effects against photobleaching of retinal pigments, age-linked macular degeneration, cataract, and retinitis pigmentosa. These molecules are characterized by their characteristic yellow-orange colored pigmentation and are found in significant amounts in vegetables such as corn, spinach, broccoli, carrots as well as fish and eggs. Unique structural signatures including tetraterpenoid skeleton with extensive conjugation and the presence of hydroxyl groups at the end rings have made these molecules evolutionarily adapted to localize in the membrane of the photoreceptor cells and prevent their free radical induced peroxidation. Apart from the benefits imparted to ocular health, lutein and zeaxanthin are also known to improve cognitive function, cardiovascular physiology, and arrest the development of malignancy. Although abundant in many natural sources, bioavailability of these compounds is low owing to their long aliphatic backbones. Under the circumstances, there has been a concerted effort to develop vegetable oil-based carriers such as lipid nano-emulsions for therapeutic administration of carotenoids. This review presents a comprehensive update of the therapeutic potential of the carotenoids along with the challenges in achieving an optimized delivery tool for maximizing their effectiveness inside the body.

2024-02-19·Biotechnology and bioengineering

A robust multinutrient kinetic model for enhanced lutein and biomass yields in mixotrophic microalgae cultivation: A step towards successful large-scale productions.

Article

作者: Jihed Bentahar ; Jean-Sébastien Deschênes

Mixotrophic cultivation holds great promise to significantly enhance the productivities of biomass and valuable metabolites from microalgae. In this study, a new kinetic model is developed, explicitly describing the effect of the most influential environmental factors on both biomass growth and the production of the high-value product lutein. This extensive study of multinutrient kinetics for Tetradesmus obliquus in a mixotrophic regime covers various nutritional conditions. Crucial nutrients governing the model include nitrate, phosphate, and glucose. Using seven state variables and 13 unknown parameters, the model's accuracy was ensured through a well-designed two-factor, four-level experimental setup, providing ample data for reliable calibration and validation. Results accurately predict dynamic concentration profiles for all validation experiments, revealing broad applicability. Optimizing nitrogen availability led to significant increases in biomass (up to fourfold) and lutein production (up to 12-fold), with observed maximum biomass concentration of 6.80 g L^-1 and lutein reaching 25.58 mg L^-1 . Noticeably, the model exhibits a maximum specific growth rate of 4.03 day^-1 , surpassing reported values for photoautotrophic and heterotrophic conditions, suggesting synergistic effects. Valuable guidance is provided for applying the method to various microalgal species and results are large-scale production-ready. Future work will exploit these results to develop real-time photobioreactor operation strategies.

项与叶黄素相关的新闻（医药）

2024-03-23

·药融圈

5.8万一瓶的“听花酒”，能用合成生物学造出来吗？

▲5月30-31日第八届广州生物医药创新者峰会扫码立即报名注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需得到授权。315晚会刚结束，主攻高端人士“听花酒”就以其5万8的天价和其疑似“智商税”的功效宣传迅速成为普罗大众讨论的焦点。在听花酒的工作人员口中，其白酒产品含有“高科技成分”，在提升免疫力、改善睡眠、保障男性功能、调节生理紊乱、抗衰老等方面均有好处，甚至请来了3位诺贝尔奖获得者为其背书，宣称过“创建定向成分编辑酿酒工艺”，提升了风味口感，减少对人体的损害并增加益处。但根据315曝光，听花酒中的高科技成分其实是廉价的薄荷提取物（尽管听花酒独家代理公司“青海春天”对这一说法予以否认）。就连听花酒是否属于白酒这个说法都存疑，因为根据2022年6月1日实施的国家标准《白酒工业术语》规定，“白酒：不直接或间接添加非自身发酵产生的呈色呈香呈味物质”，明确了白酒中不得使用食品添加剂。那么其宣称的功效可以通过合成生物学实现吗？近年来，一些初创公司通过合成生物学技术生产功效性成分，例如人参皂苷，红景天苷，麦角硫因等，但最终都以高纯度的原料形式出现，并售卖给下游厂商进行进一步加工成保健品，化妆品等。但酒类本身就是发酵产品，如果想要让白酒增加额外的功能，提升风味，降低有害物质，只需要对发酵所用的菌株进行改造即可，而这早有先例。2004年，江南大学就通过微生物代谢途径和风味物质调控规律的研究以及采用细胞工程、基因工程和代谢工程等生物技术手段实现酿酒过程中微生物代谢途径和风味物质调控。近年来，初创公司通过合成生物学改造酿酒过程也屡见不鲜。在口感提升方面，Berkeley Yeast改造了酿酒菌株可以将番石榴、菠萝等额外的风味带入低度酒中，也可以引入低度酒的主要风味物质啤酒花，让酒的味道更浓郁。另外一个提升口感的方法就是降低发酵过程中产生的杂醇，杂醇过多会带来使人难以忍受的苦涩怪味。传统的方法是对对辅料预先进行清蒸处理，在蒸酒的过程中进行“掐头去尾”，头酒和尾酒都不能作为成品售卖，需要单独存放进一步的处理。而这些杂醇可以通过专门的酶进行降解，相应的例子是Voodoo Scientific对伏特加到龙舌兰酒等蒸馏酒口味优化。那么在酒中引入功效性成分，好像也没那么难了。目前已经被报道的白酒的成分就有1000多种，其中已被证实的挥发性功效成分就有100多种，但这些成分大约只占总成分的2%左右。合成生物学对于微生物理性改造的能力可以使得其能够在生产时定向调控这些微量有益物质的含量，甚至是引入更多的非白酒成分，使得白酒更加“健康化”。图源[1]图源[2]好了，到这里可以确认，利用合成生物学技术确实可以造出一瓶类似的酒。虽然“听花酒”被诟病的是其虚假宣传，也没啥技术含量，但其宣传思路总体方向值得学习，“差异竞争”什么时候都管用。这和近年大火的褪黑素，叶黄素软糖有些类似，虽然因为工艺问题添加量可能不多，但老产品的新形式和概念往往更具有市场吸引力。而这些就是合成生物学可以对传统行业的赋能的地方。资料来源：[1] 健康白酒的研究进展[2] 中国白酒中健康因子及其富集途径的研究进展版权声明：本文转自synbio深波，如不希望被转载的媒体或个人可与我们联系，我们将立即删除活动推荐 8月 • 第六届CMC-China博览会关键词：生物药、小分子创新药、药学CMC&创新&CXO、原辅包（点击下方图片查看详情）▼【关于药融圈】药融圈PRHub旨在帮助生物医药科技型企业进行品牌推广及商务拓展服务，针对客户的真实需求制定系统化解决方案，通过“翻译-降维-场景化”将客户的品牌信息以直白易懂的方式被公众知悉，同时在流量渠道覆盖100万+垂直用户基础上实现合作目的，帮助合作伙伴完成从品牌开始到商务为终的闭环营销服务。我们已经完成了数十场线下1000人规模的生物医药研发类会议，涵盖小分子新药，大分子新药，改良型新药，BD跨境交易等多个领域，服务了百余家上市/独角兽/生物技术/制药企业。

微生物疗法基因疗法临床研究

2024-03-18

·药渡Daily

新诺威的重生之旅

三十六计中，有一计暗渡陈仓，非常精彩。去年下半年开始，新诺威一顿猛如虎的操作吸引了市场的极大关注，然而在如此高调之下，隐藏的却是石药集团诸多野心。的确，商场如战场，如何以最小的代价盘活手中筹码，如何在危急时刻还能将上一军，需要足够的智慧和谋略。经历数十年的风雨，石药集团最不缺的就是智慧与谋略，通过一系列运筹帷幄，再次给市场上了一课。如今陈仓已然暗渡成功，胜利或许只是时间问题而已。最初的模样3月15日，新诺威发布最新年报，2023年，其总营收25.02亿元，同比下降4.75%；净利润7.56亿元，增长4.03%；归母扣非净利润7.44亿元，增长13.09%。其中，功能性原料收入21.2亿元，保健食品类产品收入3.2亿元。这是新诺威装入新资产后的首份成绩单，不过显然，新资产尚未并表，这份成绩单的财务数据并不能反应其目前的真实状况。新诺威2023年营收组成来源：年报最初的新诺威主营业务为合成咖啡因的产销。无水咖啡因是一种黄嘌呤生物碱化合物，除存在于如茶叶、巧克力、咖啡豆、可可籽、槟榔、可乐果等多种植物中，也可经由人工合成。咖啡因被作为食品添加剂常被添加至软饮料及能量饮料中，同时，在临床上也可用于昏迷复苏。正是由于咖啡因拥有的特点，其于2013年被列入《第二类精神药品品种目录》，属于国家第二类精神药品，生产受到严格管控。目前国内仅有7家公司拥有咖啡因原料药生产资质（包括山东新华、新诺威/石药，广祥/石四药、尔康、大得利、佑华、舒兰合成），且在2019年后并无新增备案企业，竞争格局稳定，具有较高的政策壁垒。根据年报，2023年，新诺威的咖啡因类产品产能达到15654.81吨，增长8.97%，不出意外的话，稳坐国内头把交椅。下游客户中，包括百事可乐、可口可乐、红牛等国内外饮料公司的需求十分稳定。进入壁垒高、产能最大且下游需求稳定等因素，共同造就了咖啡因类产品成为新诺威“现金奶牛”的角色。咖啡因原料药CDE生产备案登记情况来源：申万宏源研报2016年，新诺威通过收购实控人石药集团旗下的河北果维康及中诺泰州，获得了功能性食品的相关业务；2022年，通过定增再次并购石药集团旗下的石药圣雪，获得圣雪旗下的阿卡波糖原料药及无水葡萄糖相关业务。新诺威的保健食品类产品，结合品类市场容量，选取8大品类，构建了果维康膳食营养产品矩阵，包括维生素C、维生素B族、氨糖、钙、蛋白粉、辅酶Q10、叶黄素、褪黑素及其他新品补充，覆盖“增强免疫力”的基础需求、“骨骼健康、改善睡眠、肠胃养护、抗氧化”功能需求以及“调节三高”的慢病保健需求。但这部分收入在2023年录得21.07%的下跌。阿卡波糖原料药的销售却较为乐观，2023年生产量197.84吨，增长39.75%；销售量193.68吨，增长38.36%。虽然已经经历两轮集采，但阿卡波糖仍为国内非胰岛素类降糖药的主要品种之一，制剂国产化进程持续深化。根据药渡数据，2023年前三季度，国内阿卡波糖制剂的销售额11.57亿元。国内阿卡波糖仿制药主要以阿卡波糖片为主，共有16家厂商获得批文，其中包括石药欧意、中美华东、海正药业等。但是在阿卡波糖原料药方面，目前国内仅有4家厂商持有阿卡波糖原料药生产文号，分别为新诺威、华东医药、海正药业、丽珠新北江。其中新诺威为龙头老大，2023年市占率约39%。国内阿卡波糖原料药2023年竞争格局来源：华泰证券研报从上述新诺威主营业务可以看出，不论是咖啡因还是阿卡波糖原料药，都具备了壁垒高、市占率高、需求稳定的特点，而正是这些特点，使得母公司石药集团才敢将尚未盈利的创新药资产装入新诺威。一系列的并购重组，使得新诺威正在成为一颗冉冉升起的“明星”。重生之我要当Biotech新诺威已经不是以前的新诺威了，现在的新诺威连公司名称都十分霸气----石药创新制药股份有限公司。如此“招摇”意在表明当前的新诺威已经装下石药集团的灵魂，450亿元的市值说明了一切。石药集团这一招“暗度陈仓”已经成为港股回A的经典案例，十分精彩。这一切得从去年8月底说起。2023年8月，新诺威公告正在筹划对巨石生物实施现金增资，以取得巨石生物51%以上的股权，并实现对其控股；9月，新诺威公布增资方案，以现金方式增资，总金额18.71亿元，其中10.41亿元计入巨石生物注册资本，8.3亿元计入巨石生物资本公积。2024年1月，新诺威再发布公告，因筹划发行股份及支付现金购买资产并募集配套资金，因构成重大资产重组而停牌。收购对象又是同门师兄弟，即收购同为石药集团旗下的百克（山东）生物制药股份有限公司（“石药百克”）100%股权。根据公布的交易预案，此项收购交易中现金支付比例不超过10%，其余部分以发行股份方式支付。装入创新资产后，新诺威摇身一变，成为了闪亮的Biotech，立马变得“高贵”起来。先说石药百克，其是石药集团最大的生物医药产业基地之一，已上市产品“津优力”（聚乙二醇化重组人粒细胞刺激因子注射液）是我国第一个拥有自主知识产权的长效重组人粒细胞刺激因子注射液，是国家生物1类新药，在非髓性恶性肿瘤治疗方面具有显著疗效，被列入国家重大新药创制专项。津优力也是石药集团原有的三大核心产品之一，根据药渡数据显示，2021-2023年前三季度，津优力均占据国内聚乙二醇化重组人粒细胞刺激因子市场份额的头把交椅，销售额分别为23.31亿元（市占率38.16%）、25.99亿元（市占率40.12%）和22.13亿元（市占率39.84%）。国内2023年前三季度聚乙二醇化重组人粒细胞刺激因子市场格局来源：药渡数据然而石药百克的创新含量还是不够高，要论真正的含金量，还得看巨石生物。巨石生物虽然未能独立IPO，但已战绩斐然，其中最耀眼的成绩便是成功斩获国内首款新冠mRNA疫苗。截至目前，巨石生物在研项目20余个，除新冠mRNA疫苗外，还有8款产品在国内开展不同阶段临床试验或正在申报上市（其中2款处申报上市阶段，3款处于临床II/III期，5款处临床I期）。巨石生物研发管线来源：华泰证券研报巨石生物拥有国内首个商业化mRNA稀缺平台，新冠mRNA疫苗的获批已说明该平台的先进性，后续mRNA管线在研重磅仍有狂犬、呼吸道合胞病毒、带状疱疹、HPV治疗苗等，其中狂犬/呼吸道合胞病毒疫苗已申报临床。巨石生物还拥有采用酶法定点偶联技术的ADC平台，从该平台产出的四款ADC产品已进入临床阶段（HER2 ADC，Nectin4 ADC，CLDN18.2 ADC，EGFR ADC），此外还包括三款临床前品种ROR1 ADC、HER3 ADC及HER2分子胶ADC。自2022年以来，巨石生物的两款处于I期临床的ADC药物已经实现“出海”，分别为药物SYSA1801和药物SYS6002（Nectin4 ADC），前者为其带来2700万美元首付款，11.5亿美元的里程碑付款；后者为其带来750万美元首付款，6.85亿美元里程碑付款。能够成功“出海”已尽显巨石生物ADC平台的研发实力，进展最快的HER2 ADC目前已处于临床III期，有望在2025年批准上市。此外，巨石生物的研发管线中，还包含了PD-1和一众生物类似药。PD-1恩朗苏拜单抗已经递交上市申请，有望于今年获批上市；生物类似药中，奥马珠单抗已递交上市申请，后续管线中还有乌司奴单抗类似药、帕妥珠单抗类似药，均已进入临床III期。如今石药集团将各项核心资产装入新诺威，通过一套“乾坤大挪移”大法，本质是利用新诺威，以及A股的高估值，实现其创新资产的曲线上市，且上市速度秒杀IPO。站在集团经营、资本运作层面，石药集团既没有丧失对新诺威、巨石生物、石药百克的控制权，还借此扩股增资得到一笔资金，最关键的是，经过一番炒作，新诺威的市值已然得到实质提升，一脚迈入中等药企规模。这番炒作，一箭多雕，实在高明。结语如今的新诺威，确实可称得上是A股市场上难得的优质资产，既有功能性原料和成熟药物双保险保障基础业绩，又有巨石生物提供未来想象力。当然，在如今泥沙俱下的时期，市场对这般富有权谋的资本运作保持保守态度，也是意料之中。但不可否认的是，石药集团经过这一番辗转腾挪，确实实现了其初步目的。后续发展如何，药渡还将持续关注。参考资料新诺威年报、官网、公告等申万宏源、华泰证券研报《恒瑞医药迎来最强对手？》，医曜，2024-02-28

财报并购

2024-03-06

·PRNewswire

Puritan's Pride Steadily Expands Its Global Influence, Securing a Leading Position Among Nutritional Brands

NEW YORK, March 6, 2024 /PRNewswire/ -- As global health awareness has increased, there has been a notable shift in people's focus from "treatment" to "prevention" of diseases. On December 4, 2023, the International Self-Care Foundation and the Dietary Guidance Committee of the Chinese Aging Well Association (CAWA) jointly organized the 2023 China Nutrition and Health Industry High-Quality Development Conference. Renowned Chinese experts delivered thematic speeches and participated in panel discussions on nutrition and health issues. Throughout the conference, experts analyzed the current state of cardiovascular research and made predictions for the future of cardiovascular disease. Puritan's Pride™, a global brand, was honored with the Cardiovascular Health Outstanding Contribution Award during the event. In addition, its Coenzyme Q10 product line was recognized with the 2023 Dietary Guidance Committee of CAWA Recommended Product Award. Continue Reading Puritan’s Pride Steadily Expands Its Global Influence, Securing a Leading Position Among Nutritional Brands Puritan's Pride™ prioritizes providing high-quality nutritional diet services to all families. With a strong emphasis on health and nutrition, the company uses advanced scientific research and patented technologies to create products from high-quality, safe natural ingredients. It has established itself as one of the leading nutritional supplement brands, boasting a customer base of more than six million satisfied individuals. Puritan's Pride™ is the preferred choice for people seeking health supplements, excelling in both quality and affordability. Puritan's Pride™ is a leading health supplement company established in 1973 in Long Island, New York. It boasts a rich history spanning 51 years. As one of the largest and most comprehensive health supplement companies in the United States, it specializes in the development, production, and sale of vitamins, minerals, herbs, and other health, beauty, and weight loss products, offering a range of more than 1200 nutritional products. With Coenzyme Q10, Lutein, and Lycopene as its star products, all products are certified by the U.S. FDA. Puritan's Pride has expanded its product reach to more than 90 countries and regions globally, with a monthly production capacity of up to 2.15 billion pills since its establishment. SOURCE Puritan's Pride

100 项与叶黄素相关的药物交易

登录后查看更多信息

研发状态

适应症	最高研发状态	国家/地区	公司
-	无进展	德国更多	DSM Nutritional Products AG 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


CAREDS (ARVO2021)	N/A	年龄相关疾病 lutein \| zeaxanthin	487	Lutein and zeaxanthin supplement use	壓艱餘積蓋遞艱艱糧鹹(鑰繭糧鬱顧衊鹽鑰顧遞) = 糧鏇醖膚鑰齋鏇夢窪淵範遞衊繭顧顧築糧鬱窪 (鏇遞窪襯窪鬱鹽衊艱鹹, 0.03) 更多	积极	2021-06-01
ARVO2011	N/A	-	-	Lutein	簾簾淵鹽淵衊獵遞繭壓(醖簾蓋繭夢顧網選夢觸) = 衊繭鹽餘選願壓艱窪膚淵繭鏇築艱醖窪膚醖築 (憲願淵構窪蓋構獵壓選 )	-	2011-04-01
				(3R, 3’R)-zeaxanthin	簾簾淵鹽淵衊獵遞繭壓(醖簾蓋繭夢顧網選夢觸) = 廠糧襯鑰鹹壓構選範鏇淵繭鏇築艱醖窪膚醖築 (憲願淵構窪蓋構獵壓選 )
Pubmed \| J Matern Fetal Neonatal Med	N/A	早产儿视网膜病变	-	Lutein and zeaxanthin	觸願鹽糧製壓壓選壓壓(鹹網網選糧積憲簾構艱) = 鏇糧艱餘憲鑰選膚鏇積廠構網鹹窪蓋夢觸築壓 (觸衊繭艱艱繭遞淵鏇選 )	不佳	2012-05-01
				Lutein (Placebo)	觸願鹽糧製壓壓選壓壓(鹹網網選糧積憲簾構艱) = 壓鑰艱願簾糧憲衊範顧廠構網鹹窪蓋夢觸築壓 (觸衊繭艱艱繭遞淵鏇選 )
ARVO2014	N/A	sC5b-9	-	Lutein	選淵網網築廠顧鏇衊糧(蓋顧顧艱窪鹹鹽壓願觸) = 製積廠鏇獵選艱鹹鏇構簾顧蓋構餘鏇壓鏇選齋 (範衊遞艱鏇衊壓艱鏇醖 )	积极	2014-04-01
				Lutein	選淵網網築廠顧鏇衊糧(蓋顧顧艱窪鹹鹽壓願觸) = 簾夢簾積獵築餘願鹹選簾顧蓋構餘鏇壓鏇選齋 (範衊遞艱鏇衊壓艱鏇醖 )
ARVO2009	N/A	serum lutein \| macular pigment	-	Lutein	鏇網窪鬱繭醖獵鬱糧構(網憲觸遞醖積顧憲鬱醖) = 0.0-0.39 繭願簾鏇齋獵衊鏇製齋 (窪鏇窪廠製鬱醖壓淵製 ) 更多	-	2009-04-01
ARVO2015	N/A	早发性老年性黄斑变性	-	Lutein-enriched egg-yolk dairy drink	(簾壓鹹夢鬱鬱願願醖鏇) = 築範鏇餘願壓願淵觸鏇選鏇蓋艱繭網憲簾糧窪 (廠獵鏇遞齋淵鬱餘簾糧 ) 更多	积极	2015-06-01
				lutein-enriched egg-yolk	(簾壓鹹夢鬱鬱願願醖鏇) = 憲製淵鏇遞壓憲衊廠遞選鏇蓋艱繭網憲簾糧窪 (廠獵鏇遞齋淵鬱餘簾糧 )
S4.006 (AAN2018)	N/A	疾病进展 \| 帕金森病	706	Highest quintile of lutein intake	-	积极	2018-04-10
				Highest quintile of vitamin E intake
ARVO2008	N/A	MPOD \| PERG	1	Lutein and Zeaxanthin	積糧襯選膚範衊繭願鹹(廠蓋憲鑰餘夢鏇襯觸築) = 膚鹹鬱築鹹構簾繭醖築醖齋範鏇廠鏇壓廠構觸 (鏇鏇網鑰鬱襯艱糧膚夢 )	-	2008-05-01
ARIC Study (ARVO2014)	N/A	糖尿病性视网膜病变	-	High lutein intake	鬱願積齋網艱繭艱築鹽(鏇鏇襯鬱製鏇夢鹽衊膚) = 艱夢蓋製網範製遞鏇憲繭齋壓膚鏇廠膚蓋夢糧 (構壓鹽淵鏇鬱夢鏇鹹餘 )	不佳	2014-04-01
				Low lutein intake	-
ARVO2016	N/A	角膜内皮细胞损失	-	lutein-based dyes	(艱衊範醖繭夢蓋壓簾醖) = 顧膚鹽糧鑰憲廠遞醖夢壓衊壓膚襯餘鏇鏇鑰齋 (範憲齋簾餘積觸壓齋蓋 ) 更多	-	2016-05-01
				Phacodyne TM	(艱衊範醖繭夢蓋壓簾醖) = 襯壓憲醖醖壓鑰繭艱範壓衊壓膚襯餘鏇鏇鑰齋 (範憲齋簾餘積觸壓齋蓋 ) 更多